Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Oncolytics Biotech Inc (USA) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ONCY
Nasdaq
8731
https://www.oncolyticsbiotech.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Oncolytics Biotech Inc (USA)
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
- Apr 30th, 2024 11:00 am
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
- Apr 25th, 2024 11:00 am
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
- Apr 11th, 2024 11:00 am
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
- Apr 2nd, 2024 11:00 am
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript
- Mar 10th, 2024 12:36 pm
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- Mar 7th, 2024 9:01 pm
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
- Mar 6th, 2024 1:00 pm
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
- Mar 5th, 2024 12:00 pm
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
- Mar 4th, 2024 12:00 pm
Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
- Feb 28th, 2024 12:00 pm
Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
- Feb 15th, 2024 7:41 pm
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
- Feb 15th, 2024 1:00 pm
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
- Feb 14th, 2024 12:00 pm
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
- Jan 9th, 2024 12:00 pm
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
- Jan 4th, 2024 12:00 pm
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
- Dec 7th, 2023 12:00 pm
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
- Nov 9th, 2023 12:00 pm
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep
- Nov 9th, 2023 11:30 am
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Call Transcript
- Nov 5th, 2023 7:29 pm
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
- Nov 3rd, 2023 4:03 pm
Scroll